About This Tool

The Cinqair (reslizumab) Dosing Calculator is a clinical support tool designed for healthcare professionals to determine the appropriate dose and administration parameters for patients with severe eosinophilic asthma. It simplifies the dosing process by calculating key values based on patient weight, ensuring alignment with the approved prescribing information.

Outputs Explained

After entering the patient's weight, the calculator provides the following critical information for safe and effective administration:

• Total Reslizumab Dose (mg): The precise weight-based dose (3 mg/kg) required for the patient.
• Total Volume to Withdraw (mL): The volume of Cinqair solution (10 mg/mL concentration) to be drawn from the vials.
• Number of Vials Required: The total number of 100 mg/10 mL vials needed for the calculated dose, rounded up to the nearest whole vial.

How to Use the Calculator

Using the tool is a straightforward process:

1. Enter the patient's body weight into the designated input field.
2. Select the corresponding unit of measurement, either kilograms (kg) or pounds (lbs).
3. Click the "Calculate" button to generate the dosing and preparation summary.
4. The results, along with a preparation guide, will be displayed instantly. Use the "Reset" button to clear the inputs for a new calculation.

Dosing Overview

Cinqair (reslizumab) is administered at a recommended dose of 3 mg/kg once every 4 weeks by intravenous (IV) infusion. The infusion should be administered over 20-50 minutes. Cinqair is supplied as a 100 mg/10 mL (10 mg/mL) solution in a single-dose vial. It must be diluted in a 50 mL bag of 0.9% Sodium Chloride, USP, prior to administration.

Switching Therapies

There are no specific guidelines in the prescribing information regarding a washout period when switching from other eosinophil-targeting biologics to Cinqair. Decisions on switching therapy should be made by a qualified healthcare provider based on the patient's clinical status, response to prior treatment, and risk-benefit assessment.

Missed Dose Protocol

If a patient misses a scheduled dose of Cinqair, the infusion should be administered as soon as possible. Subsequently, the dosing schedule should be adjusted to maintain a 4-week interval between infusions. Do not administer a double dose to make up for a missed dose.

Frequently Asked Questions

• What is the standard dose of Cinqair?
  The recommended dose is 3 mg per kilogram of body weight, administered once every four weeks via intravenous infusion.
• How is the total dose calculated by the tool?
  The tool multiplies the patient's weight in kilograms by 3 to determine the total dose in milligrams. If weight is entered in pounds, it is first converted to kilograms.
• Why is the number of vials rounded up?
  Since you cannot use a partial vial for a future dose, the calculator rounds up to the nearest whole number to ensure enough medication is available for withdrawal.
• Can this calculator be used for other monoclonal antibodies?
  No. This tool is calibrated specifically for Cinqair (reslizumab) and its unique concentration (10 mg/mL) and vial size (100 mg).
• How is the 'Total Volume to Withdraw' determined?
  It is calculated by dividing the total milligram dose by the drug's concentration of 10 mg/mL.
• What is the typical infusion duration?
  After dilution, the solution should be infused intravenously over a period of 20 to 50 minutes.
• Does Cinqair require reconstitution?
  No, Cinqair is a ready-to-use solution for dilution. It should not be shaken but gently inverted to mix after being added to the infusion bag.
• What diluent should be used?
  The calculated volume of Cinqair should be diluted in a 50 mL infusion bag of 0.9% Sodium Chloride, USP.

References

• CINQAEIR® (reslizumab) Prescribing Information. U.S. Food and Drug Administration. Teva Respiratory, LLC.
• Cinqair® (reslizumab) for Healthcare Professionals. Teva Pharmaceutical Industries Ltd.
• Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther. 2009;11(3):329-336.
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366. doi:10.1016/S2213-2600(15)00042-9